A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

Ian D. Davis; Juliet Quirk; Leone Morris; Lauren Seddon; Tsin Yee Tai; Genevieve Whitty; Tina Cavicchiolo; Lisa Ebert; Heather Jackson; Judy Browning; Duncan Macgregor; Frederick Wittke; Gregor Winkels; Regina Alex; Lena Miloradovic; Eugene Maraskovsky; Weisan Chen; Jonathan Cebon

doi:10.2217/imt-2016-0132

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

Ian D. Davis, Juliet Quirk, Leone Morris, Lauren Seddon, Tsin Yee Tai, Genevieve Whitty, Tina Cavicchiolo, Lisa Ebert, Heather Jackson, Judy Browning, Duncan Macgregor, Frederick Wittke, Gregor Winkels, Regina Alex, Lena Miloradovic, Eugene Maraskovsky, Weisan Chen, Jonathan Cebon

Eastern Health Clinical School

Research output: Contribution to journal › Article › Research › peer-review

13 Citations (Scopus)

Abstract

Aim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS^®plus, with initial depletion of CD1c⁺ B cells followed by positive selection of CD1c⁺ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. Conclusion: This method was feasible and safe but was minimally immunogenic.

Original language	English
Pages (from-to)	249-259
Number of pages	11
Journal	Immunotherapy
Volume	9
Issue number	3
DOIs	https://doi.org/10.2217/imt-2016-0132
Publication status	Published - 1 Mar 2017

Keywords

antigens
clinical trial
dendritic cells
ISCOMATRIX™ adjuvant
NY-ESO-1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/imt-2016-0132

Cite this

Davis, I. D., Quirk, J., Morris, L., Seddon, L., Tai, T. Y., Whitty, G., Cavicchiolo, T., Ebert, L., Jackson, H., Browning, J., Macgregor, D., Wittke, F., Winkels, G., Alex, R., Miloradovic, L., Maraskovsky, E., Chen, W., & Cebon, J. (2017). A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant. Immunotherapy, 9(3), 249-259. https://doi.org/10.2217/imt-2016-0132

@article{6f383ba4a403447aa0aa882edb4a7382,

title = "A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX{\texttrademark} adjuvant",

abstract = "Aim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX{\texttrademark} adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS{\textregistered}plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. Conclusion: This method was feasible and safe but was minimally immunogenic.",

keywords = "antigens, clinical trial, dendritic cells, ISCOMATRIX{\texttrademark} adjuvant, NY-ESO-1",

author = "Davis, {Ian D.} and Juliet Quirk and Leone Morris and Lauren Seddon and Tai, {Tsin Yee} and Genevieve Whitty and Tina Cavicchiolo and Lisa Ebert and Heather Jackson and Judy Browning and Duncan Macgregor and Frederick Wittke and Gregor Winkels and Regina Alex and Lena Miloradovic and Eugene Maraskovsky and Weisan Chen and Jonathan Cebon",

year = "2017",

month = mar,

day = "1",

doi = "10.2217/imt-2016-0132",

language = "English",

volume = "9",

pages = "249--259",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "3",

}

Davis, ID, Quirk, J, Morris, L, Seddon, L, Tai, TY, Whitty, G, Cavicchiolo, T, Ebert, L, Jackson, H, Browning, J, Macgregor, D, Wittke, F, Winkels, G, Alex, R, Miloradovic, L, Maraskovsky, E, Chen, W & Cebon, J 2017, 'A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant', Immunotherapy, vol. 9, no. 3, pp. 249-259. https://doi.org/10.2217/imt-2016-0132

TY - JOUR

T1 - A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

AU - Davis, Ian D.

AU - Quirk, Juliet

AU - Morris, Leone

AU - Seddon, Lauren

AU - Tai, Tsin Yee

AU - Whitty, Genevieve

AU - Cavicchiolo, Tina

AU - Ebert, Lisa

AU - Jackson, Heather

AU - Browning, Judy

AU - Macgregor, Duncan

AU - Wittke, Frederick

AU - Winkels, Gregor

AU - Alex, Regina

AU - Miloradovic, Lena

AU - Maraskovsky, Eugene

AU - Chen, Weisan

AU - Cebon, Jonathan

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Aim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. Conclusion: This method was feasible and safe but was minimally immunogenic.

AB - Aim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. Conclusion: This method was feasible and safe but was minimally immunogenic.

KW - antigens

KW - clinical trial

KW - dendritic cells

KW - ISCOMATRIX™ adjuvant

KW - NY-ESO-1

UR - http://www.scopus.com/inward/record.url?scp=85014055621&partnerID=8YFLogxK

U2 - 10.2217/imt-2016-0132

DO - 10.2217/imt-2016-0132

M3 - Article

C2 - 28183192

AN - SCOPUS:85014055621

SN - 1750-743X

VL - 9

SP - 249

EP - 259

JO - Immunotherapy

JF - Immunotherapy

IS - 3

ER -

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this